| ID Source | ID |
|---|---|
| PubMed CID | 5463075 |
| CHEMBL ID | 4297655 |
| SCHEMBL ID | 712083 |
| MeSH ID | M0097102 |
| Synonym |
|---|
| LMGL03012438 |
| tg(22:1/22:1/22:1) |
| tg(22:1(13z)/22:1(13z)/22:1(13z)) |
| 1,2,3-tri-(13z-docosenoyl)-glycerol |
| 13-docosenoic acid, 1,2,3-propanetriyl ester, (z,z,z)- |
| propane-1,2,3-triyl tris((z)-docos-13-enoate) |
| einecs 220-399-7 |
| erucin, tri- |
| erucic acid triglyceride |
| 13-docosenoic acid, 1,2,3-propanetriyl ester |
| glycerol trierucate |
| 1,2,3-propanetriol tri(13-docosenoate) |
| tri(z-13-docosenoyl)glycerol |
| trierucin |
| glyceryl trierucate |
| trierucate |
| 2,3-bis[[(z)-docos-13-enoyl]oxy]propyl (z)-docos-13-enoate |
| 2752-99-0 |
| 1,2,3-tri(cis-13-docosenoyl) glycerol |
| T1390 |
| glycerol tri-13-docosenoate |
| i0idq0m20r , |
| unii-i0idq0m20r |
| glyceryl tri(cis-13-docosenoate) |
| trierucin [inci] |
| (z)-13-docosenoic acid triglyceride |
| 13-docosenoin, tri-, (z,z,z)- |
| glyceryl trierucate [who-dd] |
| glyceryl trierucate [mart.] |
| glyceryl trierucate [vandf] |
| 13-docosenoic acid, 1,2,3-propanetriyl ester, (13z,13'z,13''z)- |
| SCHEMBL712083 |
| mfcd00056321 |
| J-016802 |
| 1,2,3-propanetriyl ester(z,z,z)-13-docosenoic acid |
| DB12528 |
| HY-N7055 |
| tri-13(z)-docosenoin |
| Q15726025 |
| CS-0100518 |
| CHEMBL4297655 |
| F82435 |
| MS-31902 |
| 13-docosenoic acid, 1,1',1''-(1,2,3-propanetriyl) ester, (13z,13'z,13''z)- |
| CAA75299 |
| DTXSID401021942 |
| tg 22:1_22:1_22:1 |
| AKOS040759352 |
trierucate is involved in 2 pathway(s), involving a total of 10 unique proteins and 24 unique compounds
| Pathway | Proteins | Compounds |
|---|---|---|
| Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/22:1(13Z)) | 5 | 11 |
| De Novo Triacylglycerol Biosynthesis TG(22:1(13Z)/22:1(13Z)/22:1(13Z)) | 5 | 13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2,4-dinitrophenol | dinitrophenol | allergen; antiseptic drug; bacterial xenobiotic metabolite; geroprotector; oxidative phosphorylation inhibitor | 1981 | 1981 | 43.0 | medium | 0 | 1 | 0 | 0 | 0 | 0 | |
| tristearin | triacylglycerol 54:0 | Caenorhabditis elegans metabolite; plant metabolite | 1980 | 1980 | 44.0 | medium | 0 | 1 | 0 | 0 | 0 | 0 | |
| tripalmitin | triglyceride | 1980 | 1980 | 44.0 | medium | 0 | 1 | 0 | 0 | 0 | 0 | ||
| erucic acid | docosenoic acid | 2000 | 2000 | 24.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 | ||
| triolein | triglyceride | Caenorhabditis elegans metabolite; plant metabolite | 1980 | 1996 | 33.0 | high | 0 | 1 | 3 | 0 | 0 | 0 | |
| glucagon | peptide hormone | 1981 | 1981 | 43.0 | medium | 0 | 1 | 0 | 0 | 0 | 0 | ||
| phosphatidylcholines | 1,2-diacyl-sn-glycero-3-phosphocholine | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Addison Disease and Cerebral Sclerosis | 0 | 1993 | 1996 | 29.3 | high | 0 | 0 | 3 | 0 | 0 | 0 | |
| Adrenoleukodystrophy | 1 | 1993 | 1996 | 29.3 | high | 0 | 0 | 3 | 0 | 0 | 0 | |
| Clinically Isolated CNS Demyelinating Syndrome | 0 | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |
| Demyelinating Diseases | 0 | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |
| Leukocytopenia | 0 | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |
| Leukopenia | 0 | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |
| Thrombocytopenia | 0 | 1993 | 1995 | 30.0 | medium | 0 | 0 | 2 | 0 | 0 | 0 | |
| Thrombopenia | 0 | 1993 | 1995 | 30.0 | medium | 0 | 0 | 2 | 0 | 0 | 0 |